New therapeutic approaches in diabetic retinopathy

Kamyar Vaziri, Stephen Schwartz, Nidhi Relhan, Krishna Kishor, Harry W Flynn

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Diabetic retinopathy is a common microvascular complication of diabetes mellitus. It affects a substantial proportion of US adults over age 40. The condition is a leading cause of visual loss. Much attention has been given to expanding the role of current treatments along with investigating various novel therapies and drug delivery methods. In the treatment of diabetic macular edema (DME), intravitreal pharmacotherapies, especially anti-vascular endothelial growth factor (anti-VEGF) agents, have gained popularity. Currently, anti-VEGF agents are often used as first-line agents in center-involved DME, with recent data suggesting that among these agents, aflibercept leads to better visual outcomes in patients with worse baseline visual acuities. While photocoagulation remains the standard treatment for proliferative diabetic retinopathy (PDR), recent FDA approvals of ranibizumab and aflibercept in the management of diabetic retinopathy associated with DME may suggest a potential for pharmacologic treatments of PDR as well. Novel therapies, including small interfering RNAs, chemokines, kallikrein-kinin inhibitors, and various anti-angiogenic agents, are currently being evaluated for the management of diabetic retinopathy and DME. In addition to these strategies, novel drug delivery methods such as sustained-release implants and refillable reservoir implants are either under active evaluation or have recently gained FDA approval. This review provides an update on the novel developments in the treatment of diabetic retinopathy.

Original languageEnglish (US)
JournalThe review of diabetic studies : RDS
Volume12
Issue number1
StatePublished - 2015

Fingerprint

Diabetic Retinopathy
Macular Edema
Vascular Endothelial Growth Factor A
Therapeutics
Drug Therapy
Kinins
Kallikreins
Light Coagulation
Diabetes Complications
Chemokines
Small Interfering RNA
Visual Acuity
Pharmaceutical Preparations

Keywords

  • Diabetic macular edema
  • Diabetic retinopathy
  • Proliferative diabetic retinopathy
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Internal Medicine

Cite this

New therapeutic approaches in diabetic retinopathy. / Vaziri, Kamyar; Schwartz, Stephen; Relhan, Nidhi; Kishor, Krishna; Flynn, Harry W.

In: The review of diabetic studies : RDS, Vol. 12, No. 1, 2015.

Research output: Contribution to journalArticle

@article{d82713d62b9147a4975aec533051b12e,
title = "New therapeutic approaches in diabetic retinopathy",
abstract = "Diabetic retinopathy is a common microvascular complication of diabetes mellitus. It affects a substantial proportion of US adults over age 40. The condition is a leading cause of visual loss. Much attention has been given to expanding the role of current treatments along with investigating various novel therapies and drug delivery methods. In the treatment of diabetic macular edema (DME), intravitreal pharmacotherapies, especially anti-vascular endothelial growth factor (anti-VEGF) agents, have gained popularity. Currently, anti-VEGF agents are often used as first-line agents in center-involved DME, with recent data suggesting that among these agents, aflibercept leads to better visual outcomes in patients with worse baseline visual acuities. While photocoagulation remains the standard treatment for proliferative diabetic retinopathy (PDR), recent FDA approvals of ranibizumab and aflibercept in the management of diabetic retinopathy associated with DME may suggest a potential for pharmacologic treatments of PDR as well. Novel therapies, including small interfering RNAs, chemokines, kallikrein-kinin inhibitors, and various anti-angiogenic agents, are currently being evaluated for the management of diabetic retinopathy and DME. In addition to these strategies, novel drug delivery methods such as sustained-release implants and refillable reservoir implants are either under active evaluation or have recently gained FDA approval. This review provides an update on the novel developments in the treatment of diabetic retinopathy.",
keywords = "Diabetic macular edema, Diabetic retinopathy, Proliferative diabetic retinopathy, Vascular endothelial growth factor",
author = "Kamyar Vaziri and Stephen Schwartz and Nidhi Relhan and Krishna Kishor and Flynn, {Harry W}",
year = "2015",
language = "English (US)",
volume = "12",
journal = "The review of diabetic studies : RDS",
issn = "1613-6071",
publisher = "Society for Biomedical Diabetes Research",
number = "1",

}

TY - JOUR

T1 - New therapeutic approaches in diabetic retinopathy

AU - Vaziri, Kamyar

AU - Schwartz, Stephen

AU - Relhan, Nidhi

AU - Kishor, Krishna

AU - Flynn, Harry W

PY - 2015

Y1 - 2015

N2 - Diabetic retinopathy is a common microvascular complication of diabetes mellitus. It affects a substantial proportion of US adults over age 40. The condition is a leading cause of visual loss. Much attention has been given to expanding the role of current treatments along with investigating various novel therapies and drug delivery methods. In the treatment of diabetic macular edema (DME), intravitreal pharmacotherapies, especially anti-vascular endothelial growth factor (anti-VEGF) agents, have gained popularity. Currently, anti-VEGF agents are often used as first-line agents in center-involved DME, with recent data suggesting that among these agents, aflibercept leads to better visual outcomes in patients with worse baseline visual acuities. While photocoagulation remains the standard treatment for proliferative diabetic retinopathy (PDR), recent FDA approvals of ranibizumab and aflibercept in the management of diabetic retinopathy associated with DME may suggest a potential for pharmacologic treatments of PDR as well. Novel therapies, including small interfering RNAs, chemokines, kallikrein-kinin inhibitors, and various anti-angiogenic agents, are currently being evaluated for the management of diabetic retinopathy and DME. In addition to these strategies, novel drug delivery methods such as sustained-release implants and refillable reservoir implants are either under active evaluation or have recently gained FDA approval. This review provides an update on the novel developments in the treatment of diabetic retinopathy.

AB - Diabetic retinopathy is a common microvascular complication of diabetes mellitus. It affects a substantial proportion of US adults over age 40. The condition is a leading cause of visual loss. Much attention has been given to expanding the role of current treatments along with investigating various novel therapies and drug delivery methods. In the treatment of diabetic macular edema (DME), intravitreal pharmacotherapies, especially anti-vascular endothelial growth factor (anti-VEGF) agents, have gained popularity. Currently, anti-VEGF agents are often used as first-line agents in center-involved DME, with recent data suggesting that among these agents, aflibercept leads to better visual outcomes in patients with worse baseline visual acuities. While photocoagulation remains the standard treatment for proliferative diabetic retinopathy (PDR), recent FDA approvals of ranibizumab and aflibercept in the management of diabetic retinopathy associated with DME may suggest a potential for pharmacologic treatments of PDR as well. Novel therapies, including small interfering RNAs, chemokines, kallikrein-kinin inhibitors, and various anti-angiogenic agents, are currently being evaluated for the management of diabetic retinopathy and DME. In addition to these strategies, novel drug delivery methods such as sustained-release implants and refillable reservoir implants are either under active evaluation or have recently gained FDA approval. This review provides an update on the novel developments in the treatment of diabetic retinopathy.

KW - Diabetic macular edema

KW - Diabetic retinopathy

KW - Proliferative diabetic retinopathy

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=84947577416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947577416&partnerID=8YFLogxK

M3 - Article

C2 - 26676668

AN - SCOPUS:84947577416

VL - 12

JO - The review of diabetic studies : RDS

JF - The review of diabetic studies : RDS

SN - 1613-6071

IS - 1

ER -